BleeMACS: rationale and design of the study.

J Cardiovasc Med (Hagerstown)

aDipartimento di Scienze Mediche, Divisione di Cardiologia, Città della Salute e della Scienza, Turin, Italy bUniversity Clinical Hospital, Santiago de Compostela, Spain cUniversity Academic Medical Center, Amsterdam, The Netherlands dNorthShore University Hospital, Chicago, Illinois, USA eLibin Cardiovascular Institute of Alberta, Calgary, Canada fSan Carlos Hospital, Madrid gBellvitge Hospital, Barcelona, Spain hAnzhen Hospital, Beijing, China iUniversity Patras Hospital, Athens, Greece jKerckhoff Heart and Thorax Center, Frankfurt, Germany kUniversity Clinical Hospital, Kyoto, Japan lUniversity Clinical Hospital, Warsaw, Poland mInstitute of Heart, Lung and Blood Vessel Disease, Beijing, China nTokai University School of Medicine, Tokyo, Japan oUniversity Bahian Medical School, Salvador, Brazil pDivision of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan qUniversity Clinic of Cardiology, Skopje, Macedonia.

Published: October 2016

Background: Bleeding events after an acute coronary syndrome have a negative impact on prognosis. Available risk scores are limited by suboptimal accuracy, prediction of only in-hospital events and absence of patients treated with new antiplatelet agents in the current era of widespread use of percutaneous coronary intervention.

Design: The BleeMACS (Bleeding complications in a Multicenter registry of patients discharged after an Acute Coronary Syndrome) project is a multicenter investigator-initiated international retrospective registry that enrolled more than 15 000 patients discharged with a definitive diagnosis of acute coronary syndrome and treated with percutaneous revascularization. The primary end point is the incidence of major bleeding events requiring hospitalization and/or red cell transfusion concentrates within 1 year. An integer risk score for bleeding within the first year after hospital discharge will be developed from a multivariate competing-risks regression.

Conclusion: The BleeMACS registry collaborative will allow development and validation of a risk score for prediction of major bleeding during follow-up for patients receiving contemporary therapies for acute coronary syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.2459/JCM.0000000000000362DOI Listing

Publication Analysis

Top Keywords

acute coronary
16
coronary syndrome
16
bleeding events
8
patients discharged
8
major bleeding
8
risk score
8
bleeding
5
coronary
5
bleemacs rationale
4
rationale design
4

Similar Publications

Background: Nursing care is important and necessary for Acute Coronary Syndrome patients who have undergone angiography and stenting, to minimize complications. The purpose of this study was to assess the effects of High-Quality Nursing Interventions on the quality of life and cardiac index of Acute Coronary Syndrome patients, treated with drug-eluting stents.

Methods: In this randomized trial, 70 patients of the cardiac intensive care units in one of Jahrom university of medical sciences hospitals (Iran) were selected from July 2023 to October 2023 by the available method, and randomly allocated (stochastic assignment) to two intervention (High-Quality Nursing Interventions) and control groups (routine nursing care).

View Article and Find Full Text PDF

Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.

Nat Med

January 2025

Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.

Allogeneic chimeric antigen receptor (CAR) T cells targeting disialoganglioside-GD2 (ALLO_GD2-CART01) could be a therapeutic option for patients with relapsed or refractory, high-risk neuroblastoma (r/r HR-NB) whose tumors did not respond to autologous GD2-CART01 or who have profound lymphopenia. We present a case series of five children with HR-NB refractory to more than three different lines of therapy who received ALLO_GD2-CART01 in a hospital exemption setting. Four of them had previously received allogeneic hematopoietic stem cell transplantation.

View Article and Find Full Text PDF

Objectives: The benefit of combining multiple mechanical circulatory support (MCS) systems in patients with cardiogenic shock (CS) is debated. This review examines patient characteristics across studies to identify differences and assesses if patients with a higher-risk clinical profile receive Impella unloading.

Design: A systematic review and meta-analysis was conducted to examine if there were significant differences in baseline clinical parameters among patients receiving MCS in addition to venoarterial extracorporeal membrane oxygenation (VA ECMO).

View Article and Find Full Text PDF

Axillary dose restriction (ADR) is rarely implemented in breast cancer radiotherapy by radiation oncologists to minimize exposure to organs at risk (OARs), particularly the axilla. This prospective randomized controlled study aims to evaluate the efficacy of ADR in improving plan quality (PQ) and its impact on acute radiation dermatitis (ARD) in breast cancer radiotherapy. The study recruited breast cancer patients who required postoperative radiotherapy but did not have an indication for axillary irradiation.

View Article and Find Full Text PDF

Objectives: Physical activity (PA) provides protective effects against cardiovascular diseases, including ischaemic heart disease. However, recommending moderate to vigorous PA (MVPA) to patients with recent acute coronary syndrome (ACS) raises concerns owing to potential risk of recurrent ACS or fatal arrhythmias. This study investigated the association between longitudinal PA changes following an ACS diagnosis and subsequent cardiovascular outcomes, including non-fatal coronary events, non-fatal stroke and cardiovascular mortality.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!